Brokerages Expect Bicycle Therapeutics Limited (NASDAQ:BCYC) to Post -$0.54 Earnings Per Share

Wall Street analysts expect Bicycle Therapeutics Limited (NASDAQ:BCYC) to report earnings of ($0.54) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Bicycle Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.59). The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Bicycle Therapeutics will report full-year earnings of ($3.18) per share for the current fiscal year, with EPS estimates ranging from ($3.30) to ($3.06). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.26) per share, with EPS estimates ranging from ($2.71) to ($1.58). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Bicycle Therapeutics.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.05. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $1.00 million. Bicycle Therapeutics had a negative net margin of 342.94% and a negative return on equity of 238.49%.

BCYC has been the subject of several analyst reports. Roth Capital initiated coverage on Bicycle Therapeutics in a research report on Thursday, November 14th. They set a “buy” rating and a $17.00 target price for the company. Zacks Investment Research upgraded Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Goldman Sachs Group upgraded Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Wednesday, September 11th. Finally, Canaccord Genuity set a $22.00 price target on Bicycle Therapeutics and gave the company a “buy” rating in a research note on Monday, September 30th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.00.

A number of institutional investors have recently added to or reduced their stakes in BCYC. Monashee Investment Management LLC acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $532,000. Pentwater Capital Management LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $642,000. Laurion Capital Management LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $1,006,000. Victory Capital Management Inc. acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $1,403,000. Finally, Atlas Venture Advisors Inc. acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $13,709,000. Hedge funds and other institutional investors own 36.27% of the company’s stock.

Shares of Bicycle Therapeutics stock traded down $0.31 during trading on Friday, hitting $8.30. The company’s stock had a trading volume of 12,584 shares, compared to its average volume of 13,177. Bicycle Therapeutics has a 52 week low of $6.24 and a 52 week high of $14.91. The firm’s 50-day moving average is $9.10.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Recommended Story: What is a dividend reinvestment plan?

Get a free copy of the Zacks research report on Bicycle Therapeutics (BCYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit